NCT05153954Completed
Quantitative ICG Fluorescence Angiography in Colorectal Surgery
Quantitative ICG Fluorescence Angiography in Colorectal Surgery (QUANTICO): a Protocol for a Prospective, Standardized, Observational, Surgeon-blinded Multi-center Trial
Source: ClinicalTrials.gov · Last updated 3 Dec 2024
Brief summary (registry, in English)
Fluorescence angiography with indocyanine green (ICG-FA) has gained increased popularity in colorectal surgery to check perfusion to the newly-formed anastomotic area and decrease the rate of postoperative anastomotic leakage. While qualitative ICG assessment has the advantage to be used instantly during the operative procedure, it does bear drawbacks (subjective assessment, dependent on factors like camera distance, ICG dose and white-light contamination). The alternative is quantitative ICG assessment, which is performed by evaluating the time-intensity curve of the ICG-FA with an external analyzing software. The procedure is showing promising results, but the methodology is still reported very heterogeneously. This study is a multi-center, prospective, standardized, surgeon-blinded observational trial. The key aspect of this study is the non-interventional design with blinding of both the qualitative and quantitative results from the ICG perfusion measurement, providing no chance of influencing the course of the operation. Assessment of perfusion will be performed postoperatively blinded to the outcome. Assessment of the pre-anastomotic area is intraoperatively performed by an image analysis software that then calculates a perfusion score based on an algorithm integrating relevant perfusion metrics. The primary outcome is the combined rate of early and late anastomotic complications within 90 days postoperatively.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 114 (actual)
- First submitted
- 24 Sept 2021
- Start date
- 31 Aug 2021
- Primary completion date
- 31 Aug 2024
- Lead sponsor
- Zealand University Hospital
- Diseases
- Colorectal cancer
- NCT number
- NCT05153954
What you commit to
- Study type: Observational
- Participants enrolled: 114
- From 31 Aug 2021 to the primary completion date, 31 Aug 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known allergy to ICG or iodine
Other
- Emergency procedure
- Pregnancy or if the patient is currently nursing
- Surgeons decide to do unblinded quantitative or qualitative ICG-FA
Who the study is looking for
- Age 18 years or older
- Capable of giving informed consent
- ASA Classification: status I-III
- Planned for PME or TME with minimally invasive approach and primary anastomosis
- Strong suspicion of or biopsy-verified sigmoid or rectal cancer Stage I-IV cancer
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Surgery, Herlev Hospital Coordinator of this site? Confirm its status | Herlev | Denmark | Unknown status |
| Department of Surgery, Zealand University Hospital Coordinator of this site? Confirm its status | Køge | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.